Drug
Brigimadlin clinical trials
Also written BI 907828.
- studies test it
- 9
- open now
- 0
- in phase 3
- 3
- first study started
- 2018
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses brigimadlin is read from its arms, and is right about nine times in ten.
Testing it · 9
- Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or BladderCompletedPhase 2Boehringer IngelheimNCT05512377Written as Brigimadlin
- A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This MedicineActive, not recruitingPhase 2Boehringer IngelheimNCT06619509Written as Brigimadlin
- This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)CompletedPhase 1Boehringer IngelheimNCT03449381Written as BI 907828
- Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated LiposarcomaCompletedPhase 2/3Boehringer IngelheimNCT05218499Written as Brigimadlin
- A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 InhibitorCompletedPhase 1Boehringer IngelheimNCT05372367Written as BI 907828
- Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated LiposarcomaCompletedPhase 3Boehringer IngelheimNCT06058793Written as Brigimadlin
- Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnPhase 2Institut BergoniéNCT06084689Written as Ezabenlimab + BI907828
- A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called GlioblastomaCompletedPhase 1Boehringer IngelheimNCT05376800Written as BI 907828 (Brigimadlin)
- Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaWithdrawnPhase 3Boehringer IngelheimNCT06370871Written as Brigimadlin
Given in every arm · 2 — brigimadlin is usual care beside what is tested
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)CompletedPhase 1Boehringer IngelheimNCT03964233Written as BI 907828
- A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the BodyCompletedPhase 1Boehringer IngelheimNCT05613036Written as BI 907828
Codes
What other systems call brigimadlin · ClinicalTrials.gg INT001508
- MeSH (NLM) C000712508brigimadlinOne source ClinicalTrials.gov
- UNII (FDA) 9A934ZAN94BRIGIMADLINConfirmed FDA, Wikidata
- Wikidata Q122688883brigimadlinConfirmed FDA, Wikidata
- NCI Thesaurus C156709BrigimadlinOne source FDA
- DrugBank DB18578One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712508 | brigimadlin | One source ClinicalTrials.gov |
| UNII (FDA) | 9A934ZAN94 | BRIGIMADLIN | Confirmed FDA, Wikidata |
| Wikidata | Q122688883 | brigimadlin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156709 | Brigimadlin | One source FDA |
| DrugBank | DB18578 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.